OREM, Utah, June 17, 2014 (GLOBE NEWSWIRE) -- ActiveCare, Inc. (OTCQB:ACAR), a leader in diabetes management and wellness services for self-insured employers nationwide, today announced the appointment of Mr. Earl Hurst as Senior Vice President of Business Development.
"Earl's extensive work experience in driving sales within the healthcare industry, makes him a key addition to lead the growth phase of ActiveCare," stated David Derrick, CEO and Chairman of ActiveCare. "Through Earl's leadership and industry relationships we look forward to significantly increasing our revenue base throughout the western region of the U.S."
Mr. Hurst has 30 years of management, sales and marketing experience within the insurance and medical device industries. He previously served as Market President of Humana Utah. Subsequent to Humana he was the Executive Vice President of Fred A. Morton & Company, the largest health insurance broker in the intermountain states.
Mr. Hurst commented, "I am excited to join ActiveCare to grow the revenue base while assisting insurance companies and other medical plan providers in curbing the economic burden of diabetes. With the anticipated sales to my extensive list of industry executives, ActiveCare will reach its goal of profitability in the near future."
About ActiveCare
ActiveCare, Inc. provides patented diabetes and chronic disease management and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease. To learn more about ActiveCare please visit www.activecare.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, regulatory uncertainty and economic pressure on the healthcare industry in particular, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with assimilating our recent acquisitions. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.